Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis

Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis. However, side effects can occur with sphingosine-1-phosphate receptor modulators. By considering short-term data across the drug class and longer...

Descripción completa

Detalles Bibliográficos
Autores principales: Comi, Giancarlo, Hartung, Hans-Peter, Bakshi, Rajesh, Williams, Ian M., Wiendl, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661009/
https://www.ncbi.nlm.nih.gov/pubmed/28905255
http://dx.doi.org/10.1007/s40265-017-0814-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661009/
https://www.ncbi.nlm.nih.gov/pubmed/28905255
http://dx.doi.org/10.1007/s40265-017-0814-1

Ejemplares similares